Research programme: eye disorder gene therapies - Applied Genetic Technologies Corporation/Biogen

Drug Profile

Research programme: eye disorder gene therapies - Applied Genetic Technologies Corporation/Biogen

Alternative Names: XLRP gene therapy

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Retinitis pigmentosa

Most Recent Events

  • 07 Jun 2016 Research programme: eye disorder gene therapies - Applied Genetic Technologies Corporation/Biogen receives Orphan Drug status for Retinitis pigmentosa in European Union
  • 02 May 2016 Pharmacodynamics data from preclinical studies in Retinitis pigmentosa released by by Applied Genetic Technologies Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top